CEO lowers price of AIDS drug after public backlash

The CEO of Turing Pharmaceuticals faced criticism worldwide after he hiked the price of a treatment for AIDS and cancer patients. The CEO of the company raised the price from $13.50 a tablet to $750 per tablet, close to a 5000% increase.

The drug Daraprim treats toxoplasmosis, a parasite that causes illness in those with weakened immune systems.
 
CEO Martin Shkreli justified the hike saying that the overall impact would be a minor one, and there are only 12,000 prescriptions for the drug a year. Shrekli added that proceeds will go toward developing a newer treatment with fewer side effects.

Turing Pharmaceuticals on Tuesday afternoon announced they would lower the cost of the life-saving drug. The new price was not released but he Shkreli stated the determination would be made in the next few weeks.

Shkreli said the reduction in price was a reaction to the outrage over the increase. 
 
Daraprim has been produced for over 62 years, and Turing Pharmaceuticals bought the rights to the drug last month from Impax Laboratories for $55 Million. 
 
Up Next:


Up Next

  • CEO lowers price of AIDS drug after public backlash
  • Drone hits Army helicopter over New York
  • An app for positive interactions among kids
  • Josephine PD shoots man who went to city hall with rifle
  • 4-year-old dies after finding gun in grandmother's purse
  • 2nd sinkhole opens up in Florida neighborhood
  • 'Decapitated body' is really Halloween decoration, police say
  • Texas Rangers unveil new renderings of Globe Life Field
  • Tim Tebow brings meals, smiles to Irma victims
  • NTSB: Pilots erred in Pence plane's LaGuardia skid